We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

Kyprolis® Meets Primary Endpoint of PFS in Head-to-Head Clinical Trial
The myeloma drug Kyprolis® (carfilzomib) has met the primary endpoint of progression-free survival (PFS) when compared with Velcade® (bortezomib) in patients with relapsed myeloma, according to Amgen/Onyx’s recent ENDEAVOR clinical trial interim analysis. Data from this kind of “head-to-head” clinical trial comparing different myeloma treatments “help considerably… to determine the best new treatment paradigm,” IMF Chairman Dr. Brian Durie writes in his blog this week

“Knowledge is Power” - Key Message of Myeloma Awareness Month

It is officially Myeloma Awareness Month (?#‎MAM?)!

The IMF first declared this global event in 2009, with the notion that increasing awareness of the disease could lead to early diagnosis and increased funding for researching.

This year, we are pushing the "Knowledge is power" message.

"The majority of patients have never heard of myeloma before their diagnosis," IMF President and Co-Founder Susie Novis said. "The IMF is proud to lead the charge in raising myeloma awareness across America and around the world."


Amgen Announces the European Medicines Agency Acceptance of Kyprolis® (carfilzomib) Marketing Authorization Application for the Treatement of Relapsed Multiple Myeloma
Kyprolis (carfilzomib) is currently under accelerated review by the European Medicines Agency (EMA) for treatment of patients with relapsed multiple myeloma who have received at least one prior therapy! "Achieving deep and durable responses for patients with relapsed multiple myeloma is critical towards extending the time they live without their disease progressing," said Pablo J. Cagnoni, M.D., president, Onyx Pharmaceuticals, Inc. "We look forward to working with European regulators to potentially make this important medication available."

FDA Reverses ODAC Vote and Approves Panobinostat for Relapsed Myeloma - Read Dr. Durie's blog
The US Food and Drug Administration (FDA) on Monday approved panobinostat for the treatment of myeloma. Marketed by Novartis under the name Farydak, panobinostat is an HDAC inhibitor intended for patients who have received at least two prior therapies. The safety and efficacy of panobinostat, which is used in combination with bortezomib and dexamethasone, was demonstrated in 193 clinical trial participants. "The approval is obviously good news for the myeloma community," IMF Chairman Dr. Brian Durie reports in his blog.

IMF Launches New Resource Page for Ixazomib
In response to the interest in Takeda’s ixazomib, an oral proteasome inhibitor, the IMF has assembled a new resource page on its website that provides a rundown on the drug’s progress through clinical trials. In one of its four ongoing Phase III trials, ixazomib recently achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis.

FDA Approves Farydak (Panobinostat) For The Treatment Of Multiple Myeloma
In November 2014, the FDA’s Oncologic Drugs Advisory Committee advised the agency that, based on the data reviewed, the drug’s benefits did not outweigh its risks for patients with relapsed multiple myeloma. After the meeting, the company submitted additional information supporting Farydak’s use for a different indication: patients with multiple myeloma who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent.

New IMWG Assessment System for Elderly Myeloma Patients
The IMF’s research arm, the International Myeloma Working Group (IMWG), published an important new study on the assessment of elderly myeloma patients in the journal Blood. In the paper, the IMWG introduces a scoring system developed to classify the frailty of elderly patients. The international study, which analyzed data from more than 850 newly diagnosed patients, found that the IMWG frailty score predicted mortality and the risk of toxicity in elderly myeloma patients. The frailty score could be a helpful tool in better assessing patients and providing them with more suitable therapies

EC approves Revlimid for Treatment of Previously Untreated Myeloma Patients Not Eligible for Transplant
REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant

Revlimid receives frontline approval in the US
There was important news for myeloma patients this week as the US Food and Drug Administration approved Revlimid in combination with dexamethasone for newly diagnosed myeloma patients. Revlimid has already been in frontline use off-label in the US, but as IMF Chairman Dr. Brian Durie writes, the new approval raises “many issues which will limit ideal global access and use.” CLICK HERE to read Dr. Durie's blog.

Share Your Story for Myeloma Awareness Month
With less than a month until March begins, the IMF is getting the ball rolling on Myeloma Awareness Month (#MAM). Sharing your story with even one person can help spread awareness, but with the internet at your fingertips, your story has the potential to inspire and educate thousands. Stories from patients and caregivers can inspire others to get their symptoms checked or go for a screening they’d been putting off. These stories also provide hope and support to people who may be going through difficult times. CLICK HERE to share your story, a lesson, or a piece of advice.

previous     next      view all